Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P15309

UPID:
PPAP_HUMAN

ALTERNATIVE NAMES:
5'-nucleotidase; Acid phosphatase 3; Ecto-5'-nucleotidase; Protein tyrosine phosphatase ACP3; Thiamine monophosphatase

ALTERNATIVE UPACC:
P15309; D3DNC6; Q5FBY0; Q96KY0; Q96QK9; Q96QM0

BACKGROUND:
The protein Prostatic acid phosphatase, with alternative names such as 5'-nucleotidase and Acid phosphatase 3, plays a crucial role in various biological processes. It dephosphorylates a wide range of substrates, has lipid phosphatase activity, and inactivates lysophosphatidic acid. Its tumor suppressor function in prostate cancer and ecto-5'-nucleotidase activity in neurons highlight its multifaceted role. The protein's involvement in forming SEVI amyloid fibrils that enhance HIV infection further underscores its biological significance.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional nature of Prostatic acid phosphatase offers promising avenues for therapeutic intervention, especially in prostate cancer treatment, pain alleviation, and potentially in strategies to mitigate HIV infection efficacy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.